◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound OPTIONAL-ADD HIGH

Copper

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict OPTIONAL-ADD HIGH

"Standalone copper supplementation is rarely needed (deficiency is uncommon on a varied diet), but it is essentially mandatory as a copper-zinc balance counterweight for anyone supplementing 25+ mg zinc daily long-term. 1-2 mg copper per 15-30 mg zinc keeps the ratio safe and prevents copper-deficiency neuropathy/anemia (44%+ of zinc-induced copper-deficiency myelopathy cases never recover full neurologic function — Jaiser & Winston 2010 systematic review of 55 cases). For an MMA athlete on Dylan's V4 zinc 25mg/day stack, copper inclusion is a near-mandatory minor add. archetype reinforcement: at 20 with daily zinc supplementation, the copper counterweight is cheap insurance against an irreversible neurologic outcome."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload, on zinc supplementation (Dylan / this-archetype)
    STRONG-CANDIDATE

    / OPTIONAL-ADD, HIGH confidence. Copper bisglycinate 2 mg / day is essentially mandatory counterweight to V4 zinc 25 mg/day. The supplementation prevents an irreversible neurologic outcome at trivial cost (~$0.20/day). DBH cofactor role pairs with V5 dopaminergic nootropic plans (modafinil, bromantane) — copper sufficiency supports NE biosynthesis from elevated dopamine pools. Lysyl oxidase role pairs with MMA-training tendon/ligament durability. Decision: ADD to V5 immediately as cheap-insurance maintenance supplement.

  • ★20-30, brain-priority, NOT supplementing zinc, balanced diet
    NOT-INDICATED

    Food copper from organ meats, shellfish (especially oysters — ~5-7 mg per serving), cashews, almonds, sesame seeds, dark chocolate is sufficient. Solo supplementation provides no clear benefit. Skip.

  • 30-50, executive maintenance, on chronic zinc
    STRONG-CANDIDATE

    Same logic as Dylan archetype. Add 1-2 mg copper bisglycinate.

  • 30-50, executive maintenance, no zinc
    NOT-INDICATED

    Same as above — varied diet is sufficient.

  • 50+, on zinc (cold/immune/prostate)
    STRONG-CANDIDATE

    / HIGH confidence. Older adults are at higher risk of GI absorption issues + denture-cream zinc co-exposure; the deficiency pathway has more entry points. Add 1-2 mg copper. Monitor labs annually.

  • 50+, not on zinc, concerned about Alzheimer's
    NOT-INDICATED

    to supplement. Some evidence that elevated unbound serum copper correlates with Alzheimer's pathology. Aim for adequacy via diet, not supplementation.

  • Athletic male 18-35 on zinc (broader category beyond Dylan)
    STRONG-CANDIDATE

    auto-add. Whenever a stack pairs daily zinc 25+ mg with chronic high-load training, add 1-2 mg copper bisglycinate. Same as Dylan archetype.

  • Combat-athlete (MMA / BJJ / boxing / Muay Thai — Dylan profile specifically)
    STRONG-CANDIDATE

    / HIGH confidence. The lysyl-oxidase-mediated collagen/elastin cross-linking pathway is mechanistically relevant for tendon/ligament integrity in a sport with daily high-volume joint stress. No direct RCT in this population, but the cost is trivial and the deficiency-prevention rationale is strong even without the LOX angle. Add. Pairs cleanly with V4 zinc, supports V5 modafinil/dopaminergic plan via DBH cofactor role.

  • Post-bariatric / gastric surgery (regardless of age)
    STRONG-CANDIDATE

    / HIGH confidence. Copper absorption is impaired post-surgery. Many post-bariatric patients develop copper deficiency myeloneuropathy years after surgery — Jaiser & Winston 2010 series, Spinazzi 2007 case. Routine copper supplementation + annual monitoring is standard of care. 2-4 mg / day.

  • Anemia of unknown cause, with normal B12/iron
    WORKUP-INDICATED

    before supplementation. Don't empirically supplement — check serum copper + ceruloplasmin + 24h urine copper + CBC + neurologic exam. If copper deficiency confirmed, treat per specialist.

  • Wilson's disease (diagnosed or suspected)
    HARD-BLOCK

    Do NOT supplement copper. Treatment is zinc + chelators (penicillamine, trientine).

  • Hereditary copper-overload disorders / aceruloplasminemia / hemochromatosis with copper-loading variant
    HARD-BLOCK
  • Biliary cirrhosis or cholestasis (cannot excrete copper via bile)
    HARD-BLOCK
  • Pregnancy
    NOT-CONTRAINDICATED

    at maintenance dose (RDA 1.0 mg/day for pregnant adults vs. 0.9 mg baseline; UL still 10 mg/day). If on prenatal vitamin, check existing copper content before adding.

  • Drug-tested athletes (WADA / USADA)
    NO CONCERN

    Copper is not a banned substance.

▸ Subjective experience (deep)

For most users at maintenance dose (1-2 mg/day): nothing acutely perceptible. Copper is a maintenance nutrient, not a stimulant or anxiolytic. Subjective benefit is the absence of deficiency symptoms — which most healthy adults don't have to begin with.

For users with sub-clinical or clinical deficiency (e.g., chronic zinc supplementation without copper, or post-bariatric surgery patients), repletion produces:

  • Energy / fatigue improvement (weeks to months) — likely cytochrome c oxidase + ceruloplasmin/iron-mobilization recovery.
  • Improved cold tolerance (anecdotal, plausible via NE synthesis).
  • Hair/skin pigmentation recovery (months) — tyrosinase normalization.
  • Resolution of unexplained anemia + neutropenia (weeks) — hematologic recovery is the fastest and most complete.
  • Stabilization (rarely full reversal) of myelopathy symptoms — this is the most important and least optimistic part. If subjective sensory ataxia, gait instability, or paresthesias have set in due to chronic deficiency, copper repletion typically halts progression but does not restore full function in many cases (Jaiser & Winston 2010 review). This is why the framing of copper in this file is prevention, not treatment-after-the-fact.

No psychoactivity at maintenance doses. A handful of community reports describe vague "mood elevation" from copper supplementation — likely either placebo or, in deficient users, recovery of normal DBH/NE function from sub-clinical depletion. Not a reliable subjective effect to expect.

At supraphysiologic doses (>10 mg acute): Nausea, vomiting, abdominal pain, metallic taste, headache. Acute toxicity territory; no benefit from this dose range. Stop and reduce.

For Dylan (this archetype): Expect to feel nothing from 1-2 mg/day copper. That is the desired outcome — the supplement is invisible insurance against an iatrogenic deficiency that you'd only notice once it had already caused damage.

▸ Tolerance + cycling deep dive
  • No pharmacodynamic tolerance. Copper is a maintenance cofactor, not a receptor agonist. Daily dosing produces no tolerance, no escalation, no withdrawal.
  • Cycling not needed. Take it daily as long as zinc supplementation continues. Stopping copper while continuing zinc is the harm scenario (recapitulates the original deficiency-induction problem).
  • If discontinuing zinc: Continue copper for ~2-4 weeks to allow the zinc-induced MT to downregulate, then stop both. No taper required.
  • If switching zinc forms or doses: Maintain copper at 1-2 mg/day throughout — the MT mechanism is qualitative not quantitative-precise.
▸ Stacking deep dive

Synergistic with

  • Zinc (this is the raison d'être of the supplementation). 8:1 to 15:1 Zn:Cu mg ratio; separate doses by ≥4h.
  • Vitamin C / ascorbate. DBH (NE synthesis) requires both copper and ascorbate as obligate cofactors. Co-sufficiency supports catecholamine biosynthesis. Note: ≥1g vitamin C taken simultaneously with copper acutely can reduce copper absorption; separate by 2h for routine dosing. Not relevant for the small ascorbate amounts in multivitamins.
  • Iron (when iron is needed). Copper sufficiency is required for ceruloplasmin-mediated iron mobilization. Iron supplementation in a copper-deficient subject is futile until copper is restored.
  • Manganese, selenium, B-complex. All trace-mineral cofactor co-sufficiencies for metalloenzyme function. No specific synergy with copper, but a balanced micronutrient base is the right hygiene.

Avoid stacking with (same-dose)

  • Zinc (same-dose) — covered above. Separate by 4-6h.
  • High-dose vitamin C (≥1g same-dose) — separate by 2h.
  • High-dose calcium (≥600 mg same-dose) — modest reduction in copper absorption; separate by 2h.
  • High-dose molybdenum (>1 mg/day) — molybdenum can complex with copper (the basis of the Wilson's drug tetrathiomolybdate). Not a practical concern at supplement doses but worth noting.
  • Antacids / PPIs chronically — gastric acid is needed for copper liberation from food/supplement matrix. Long-term PPI use modestly impairs copper absorption.

Neutral / safe co-administration

  • All of Dylan's V4 stack: magnesium, omega-3, vitamin D3, vitamin K2, NAC, citicoline, phosphatidylserine, curcumin, rhodiola, L-theanine, glycine, beta-alanine, taurine, creatine — no interactions known.
  • All planned V5 nootropic adds (modafinil, semax, selank, bromantane, peptides) — no interactions known.
▸ Drug interactions deep dive
  • D-penicillamine (Wilson's, rheumatoid arthritis): Chelates copper. Do not supplement copper concurrently with D-penicillamine — defeats the purpose of the chelator and risks chelator-induced deficiency syndromes (rare myasthenia, immune side effects). Hard contraindication.
  • Trientine (Wilson's): Same logic. No copper supplementation.
  • Zinc (therapeutic — Wilson's, sickle cell): When zinc is given as therapy specifically to block copper, do not co-supplement copper. (For Dylan's nutritional zinc 25 mg/day, this guidance is inverted — copper IS the counterweight.)
  • Tetrathiomolybdate (Wilson's, oncology investigational): Same logic. No copper supplementation.
  • Allopurinol: Theoretical reduction in xanthine-oxidase-related copper handling; no clinically significant practical interaction at supplement doses.
  • Cimetidine, PPIs (chronic high-dose): Modest impairment of copper absorption. Not a contraindication; may need slightly higher copper intake if on chronic acid suppression.
  • Oral contraceptives, HRT, estrogen therapies: Estrogen raises ceruloplasmin synthesis (ceruloplasmin is mildly estrogen-responsive). Serum copper and ceruloplasmin run higher on hormonal contraception — relevant for interpreting labs (don't mistake estrogen-driven elevation for copper overload) but not a supplementation contraindication. Relevance for Dylan: indirect (partner-relevant only).

Copper does not induce or inhibit CYP enzymes meaningfully. No pharmacokinetic drug-drug interactions of clinical significance at supplement doses.

▸ Pharmacogenomics

  • ATP7B (Wilson's disease gene). Autosomal recessive; >500 pathogenic variants. Biallelic loss-of-function → copper accumulation. Hard contraindication to copper supplementation if Wilson's is established. Carrier status (heterozygous) is generally asymptomatic and not a contraindication. For Dylan post-23andMe (June 2026): Promethease/Open SNP can flag known pathogenic ATP7B variants in raw data. Worth a quick check — extremely low pre-test probability without family history (Kayser-Fleischer rings, unexplained transaminitis, neuropsychiatric symptoms under 40), but the cost of looking is zero.

  • ATP7A (Menkes disease, X-linked). Severe pediatric copper-malabsorption syndrome. Manifests in infancy; not a consideration for adult-onset supplementation decisions.

  • CTR1 (SLC31A1). Apical copper importer in enterocytes. Common polymorphisms exist but no clear actionable supplementation guidance based on genotype.

  • CP (ceruloplasmin gene). Aceruloplasminemia is a rare autosomal recessive condition causing iron overload + neurodegeneration. Carrier status modulates ceruloplasmin levels mildly. Not actionable for routine supplementation.

  • MT (metallothionein) variants. Implicated in modulating zinc-copper handling at the enterocyte. Some emerging research linking MT polymorphisms to differential supplement response. Not yet a clinically actionable PGx target.

  • Practical PGx takeaway for Dylan: Run 23andMe raw data through Promethease (June 2026 window) and confirm no flagged ATP7B pathogenic variants. Beyond that, standard copper supplementation at 2 mg/day is appropriate regardless of common variant status.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Mainstream OTC supplement (US) Thorne, Pure Encapsulations, Designs for Health, NOW, Solgar, Jarrow $8-20 per bottle, 90-120 caps, 2-3 mg/cap High — third-party tested brands, COA available Preferred. Choose copper bisglycinate or copper glycinate explicitly on the label.
Combo zinc-copper supplement LifeExtension Zinc Caps (zinc 50 mg + copper 2 mg), Solgar Chelated Zinc + Copper, Thorne Zinc + Copper $10-25 per bottle High Convenient — single SKU covers both halves. Caveat: zinc and copper are in the same capsule, defeating the "separate by 4h" rule. Better to source as separates and dose at different meals.
Multivitamin (incidental) Thorne Basic Nutrients, Pure Encaps Daily, NOW Adam $15-30/month Medium for copper specifically Check label form — many budget multis use cupric oxide which is poorly bioavailable. Premium multis typically use copper glycinate or sulfate.
Amazon generic Various $5-10 per bottle Medium — quality variable, COA rare on budget brands Acceptable if NSF/USP-certified; otherwise prefer mainstream brand.
iHerb NOW, Solgar, Doctor's Best, Jarrow $5-15 per bottle, often discounted High Standard biohacker channel; broad selection of forms. Recommended for Dylan — pairs with existing V4 iHerb order pattern.
Bulk powder BulkSupplements (copper gluconate powder) $15-25 / 100g Medium — accurate but inconvenient (volumetric dosing of mcg-mg quantities is error-prone for a 1-2 mg target) Not recommended; capsule forms are more accurate at this dose range.

Recommended specific SKU for Dylan: Thorne Copper Bisglycinate 2 mg, 60 caps, ~$12 on iHerb — fits existing supplement-stack vendor pattern, clean ingredient (no fillers of concern), accurate label dose, copper bisglycinate form.

Alternative: NOW Foods Copper Glycinate 3 mg, 100 tabs, ~$8 on iHerb — slightly higher dose; split if targeting 1.5 mg or take as-is at 3 mg (still well below UL). Slightly cheaper option.

Sourcing-difficulty rating: easy. OTC GRAS supplement, broadly available, no legal/regulatory friction.

▸ Biomarkers to track (deep)

Baseline (before starting / during June 2026 bloodwork window for Dylan)

  • Serum copper (reference range ~70-150 mcg/dL; varies by lab). Acute-phase reactant — rises with infection/inflammation. Single timepoint less informative than trend.
  • Ceruloplasmin (reference ~20-50 mg/dL). More stable than serum copper; low ceruloplasmin is the canonical marker of copper deficiency. Also acute-phase reactant (rises in inflammation, pregnancy, estrogen exposure).
  • CBC with differential — hemoglobin, MCV (macrocytic anemia in copper deficiency, mimics B12), ANC (neutropenia is a copper deficiency hallmark).
  • Iron panel (ferritin, transferrin saturation) — to distinguish copper-deficiency anemia from iron-deficiency.
  • Vitamin B12 — to distinguish from B12-deficiency myelopathy (the differential diagnosis for copper deficiency myelopathy is B12 deficiency; both look identical clinically).
  • ALT, AST — baseline liver enzymes; useful to rule out subclinical Wilson's before supplementation.
  • Zinc level — if you're going to track ratio, you need both.
  • Zn:Cu ratio (calculated, mg/L basis). Optimal range debated; ~0.7-1.0 Cu:Zn is one commonly cited target. Inflammation-confounded.

During use (annual)

  • Serum copper + ceruloplasmin q12 months while on chronic zinc + copper combo. Confirm staying in reference range.
  • CBC + differential annually — catch any sub-clinical hematologic drift.
  • Liver enzymes annually (already covered in Dylan's annual bloodwork).
  • Subjective neurologic check — paresthesias, gait, balance. Any unexplained sensory ataxia or proprioceptive issues → urgent copper level + neuro workup. (Unlikely in a 20yo on appropriate supplementation; included for completeness.)

Advanced / research-tier biomarkers

  • RBC-SOD activity — functional copper biomarker; not routinely available in commercial labs.
  • 24h urine copper — used in Wilson's workup (elevated in Wilson's); low in deficiency. Specialist test.
  • Hair tissue mineral analysis (HTMA) — popular in functional medicine, mixed validity. Treat with skepticism; serum + ceruloplasmin are the validated tests.
  • Cu/Zn-SOD genetic variants — not standard care, mentioned for research interest.

Genetic

  • ATP7B variant check via Promethease (Dylan: post-23andMe June 2026). Pre-supplementation safety check.
▸ Controversies / open debates Live debate

  1. "Optimal Zn:Cu ratio — 8:1 or 15:1?" Clinical practice ranges. Most US clinicians target ~10:1. EFSA/EU guidance leans tighter (lower zinc, similar copper). The 8:1 floor and 15:1 ceiling come from observational cohorts; the true optimum is unknown and probably individually variable. Practical answer: anywhere in the 8:1 to 15:1 range is fine; Dylan at 12.5:1 (25 mg Zn + 2 mg Cu) is comfortably mid-range.

  2. "Copper for tendon/ligament durability in athletes — real or mechanistic-only?" Lysyl oxidase + dietary copper is well-established in animal/developmental literature. Direct RCT evidence in trained adult athletes is absent. Reasonable inference: copper sufficiency is permissive (deficiency would impair LOX → weaker connective tissue); supraphysiologic copper for tendon benefit is unsupported and unnecessary at maintenance dose. Don't oversell the tendon angle to athletes.

  3. "Copper bisglycinate vs. cheaper forms — meaningful difference?" Animal nutrition data strongly favors chelates. Human RCT data is sparse but consistent in showing cupric oxide is poorly bioavailable. Bisglycinate vs. gluconate vs. sulfate in humans is closer to a wash at maintenance dose. Practical answer: bisglycinate is the most evidence-backed choice; gluconate is acceptable; avoid cupric oxide as a primary copper source.

  4. "Solo copper supplementation for energy / mood / 'longevity' in healthy non-deficient adults — useful?" No. Community reports of "more energy" or "improved mood" on copper supplementation in already-replete adults are most likely placebo or recovery from sub-clinical deficiency. Supraphysiologic copper has no proven nootropic, ergogenic, or longevity benefit and approaches the UL.

  5. "Copper and Alzheimer's in older adults — supplement or avoid?" Some observational data link elevated unbound/non-ceruloplasmin-bound serum copper (a small fraction of total) with Alzheimer's pathology — possible role in amyloid-metal chemistry. Other data argue copper deficiency contributes to cognitive decline. Practical synthesis: in older adults, target adequacy via diet rather than supplementation; if supplementing for zinc-counterweight reasons, 1-2 mg/day is well below the dose range implicated in any toxicity signal. Not relevant for a 20yo athlete.

  6. "Repeat-user trend on dopamine.club: 43/64 neutral, 10 positive, 11 negative — what does that mean?" It means the supplement is doing what a maintenance nutrient should do — be invisible. Most users feel nothing; the small positive cohort is likely deficient-state repletion; the small negative cohort is likely GI tolerance issues (form/timing-fixable). Pattern is consistent with "well-tolerated maintenance supplement," not "high-effect intervention." Set subjective expectations to "you won't feel it" for Dylan.

  7. "Cu/Zn ratio as mortality biomarker (elderly cohorts) — relevant to a 20yo?" Largely inflammation-confounded. Elevated Cu/Zn in elderly cohorts mostly reflects chronic inflammation (ceruloplasmin rises, zinc falls) rather than copper status per se. For a young inflammation-free athlete, the ratio is a poor signal. Don't over-interpret.

  8. "GHK-Cu (copper peptide) injection — relates to this file?" Tangentially. GHK-Cu (glycyl-L-histidyl-L-lysine + Cu²⁺) is a peptide-copper complex used cosmetically (skin/hair) and investigationally (wound healing). It's a distinct intervention from oral copper supplementation — GHK-Cu delivers small amounts of copper systemically, doesn't address the zinc-deficiency balance problem, and has its own dose/safety profile. Discord anecdotes in the community-data-block about "copper uglies" relate to GHK-Cu pin scenarios, not oral copper supplementation. See GHK-Cu.md for GHK-specific guidance (not in scope for this file).

▸ Verdict change log
  • 2026-05-14 — research-pass elevated from medium → thorough. Initial OPTIONAL-ADD verdict confirmed. Verdict-rationale expanded to highlight irreversibility of copper-deficiency myelopathy (Jaiser & Winston 2010, ~50% of CDM cases have residual neurologic deficit even after Cu repletion) and Dylan-archetype-specific reinforcement (V4 zinc 25 mg/day, MMA training context, V5 dopaminergic plan via DBH cofactor role). No change to dose (2 mg/day copper bisglycinate) or core recommendation.
  • 2026-05-05 — initial OPTIONAL-ADD verdict (V6 wiki Wave E build). Auto-stub from dopamine.club community data. Established core dose (1-2 mg/day), zinc-counterweight rationale, copper bisglycinate as preferred form.
▸ Open questions / gaps Open
  1. Direct RCT of copper supplementation for tendon/ligament outcomes in trained adult athletes. Mechanistic case is strong (LOX); empirical evidence is absent. Unlikely to be funded.
  2. Pharmacogenomics of zinc-induced copper deficiency. Why do some chronic high-zinc users develop CDM and others don't? MT variants? CTR1 variants? Sparse data.
  3. Optimal long-term Zn:Cu ratio for athletes on chronic micronutrient supplementation. Most data is in elderly, deficient, or post-surgical populations. Athletic-specific data is thin.
  4. Copper bisglycinate vs. gluconate vs. sulfate head-to-head human RCT. Animal data favors bisglycinate; human data is consistent but sparse. Bioequivalence quantification is a gap.
  5. Subclinical copper deficiency prevalence in supplementing populations. Mayo Clinic 2024 data (cited in zinc-copper-balance reviews) suggests ~23% of zinc-supplementing adults screened had subclinical copper deficiency. Magnitude in younger / athletic populations specifically — unmeasured.
  6. CYP / drug-interaction surface at supplement doses. Generally absent at maintenance dose, but the systematic absence of CYP-interaction studies is a gap (vs. extensively-characterized drugs).
  7. Dylan-specific: Post-June 2026 bloodwork — check serum copper + ceruloplasmin + CBC + ATP7B raw-data flag. Validate that 2 mg/day is hitting the right target without overshooting.

References

Kumar N, Gross JB Jr, Ahlskog JE. Myelopathy due to copper deficiency. Neurology. 2003;61(2):273-274. PMID 12874423

pubmed.ncbi.nlm.nih.gov · 2003

foundational case series; CDM as treatable myelopathy.

View Study

Hedera P, Fink JK, Bockenstedt PL, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin. Arch Neurol. 2003;60(9):1303-1306. PMID 12975299

pubmed.ncbi.nlm.nih.gov · 2003

zinc-overload → Cu deficiency → myelopolyneuropathy + pancytopenia + low ceruloplasmin.

View Study

Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123(1):125-131. PMID 15762288

pubmed.ncbi.nlm.nih.gov · 2005

bone marrow phenotype (sideroblastic anemia + neutropenia) mimics MDS.

View Study

Spinazzi M, De Lazzari F, Tavolato B, Angelini C, Manara R, Armani M. Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy. J Neurol. 2007;254(8):1012-1017. PMID 17415508

pubmed.ncbi.nlm.nih.gov · 2007

phenotype extended to optic neuropathy; SIBO + occult zinc co-factors.

View Study

Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol. 2010;257(6):869-881. PMID 20232210

pubmed.ncbi.nlm.nih.gov · 2010

systematic review of 55 CDM cases; inverted-V T2 MRI signature; ~50% incomplete neurologic recovery despite Cu repletion. Anchor clinical reference.

View Study

Goodman BP. Copper Deficiency Myelopathy (Human Swayback). Mayo Clin Proc. 2011;86(10):1003-1006

mayoclinicproceedings.org · 2011

61161-0/fulltext) — Mayo Clinic CDM clinical synthesis.

View Source

NIH Office of Dietary Supplements: Copper Health Professional Fact Sheet

ods.od.nih.gov

RDA, UL, food sources, deficiency syndromes.

View Source

Linus Pauling Institute: Copper Micronutrient Information Center

lpi.oregonstate.edu

comprehensive review including cuproenzyme biology.

View Source

Wilson Disease GeneReviews (NCBI Bookshelf NBK1512)

ncbi.nlm.nih.gov

clinical/genetic reference.

View Source

Dopamine beta-hydroxylase — Wikipedia (with cited primary refs on copper-cofactor biology)

en.wikipedia.org

DBH copper/ascorbate cofactor mechanism.

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…